Overview

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

Compare efficacy and safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with a primary efficacy endpoint of 6-month seizure freedom. Noninferiority design to show a similar risk/benefit balance between Lacosamide (LCM) and Carbamazepine-CR (CBZ-CR).

Phase:

Phase 3

Details

Lead Sponsor:

UCB BIOSCIENCES GmbH

Collaborator:

Eden Sarl

Treatments:

Carbamazepine
Lacosamide